Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: study protocol for a randomised controlled trial by Nadine Aawar et al.
TRIALS
Aawar et al. Trials  (2015) 16:169 
DOI 10.1186/s13063-015-0670-9STUDY PROTOCOL Open AccessFibrinogen concentrate versus placebo for
treatment of postpartum haemorrhage: study
protocol for a randomised controlled trial
Nadine Aawar1*, Raza Alikhan2, Daniel Bruynseels3, Rebecca Cannings-John1, Rachel Collis3, John Dick4,
Christopher Elton5, Roshan Fernando4, Judith Hall3,6, Kerry Hood1, Nicki Lack7, Shuba Mallaiah8, Helena Maybury9,
Jacqueline Nuttall1, Shantini Paranjothy10, Rachel Rayment11, Alexandra Rees11, Julia Sanders1,11, Julia Townson1,
Andrew Weeks12 and Peter Collins2,6Abstract
Background: Postpartum haemorrhage (PPH) is a major cause of maternal morbidity. Bleeding is caused by a
combination of physical causes, such as failure of the uterus to contract or operations, and is made worse by
impairment of the blood clotting system. A number of studies have shown that low levels of the blood clotting
factor fibrinogen are associated with progression of bleeding, the need for invasive interventions and transfusions
of red blood cells and fresh frozen plasma (FFP). This trial will investigate whether early infusion of fibrinogen
concentrate during a major PPH, with the aim of correcting a low fibrinogen to a level that is normal for delivery,
based on the Fibtem test, reduces the total number of allogeneic blood products (red blood cells, FFP,
cryoprecipitate and platelets) transfused after study medication until discharge, compared to placebo.
Methods/design: This is a prospective, randomised, double-blind placebo controlled trial. Women will enter an
observational phase and if their Fibtem levels fall they will be randomised in the interventional phase. A total of 60
women will be randomised and women are eligible for the trial if they meet all of the following inclusion criteria:
age 18 years or over, gestation ≥24 + 0 weeks, haemorrhage of about 1500 ml and on-going bleeding without
another complication or haemorrhage of about 1000 ml and caesarean section/uterine atony/placental abruption/
placenta praevia/cardiovascular instability or microvascular oozing. Participants with a Fibtem A5 < 16 mm will be
randomly allocated to receive either a bolus infusion of fibrinogen concentrate or placebo (isotonic saline). The
dose of fibrinogen concentrate or placebo will be calculated based on the woman’s ideal body weight for height
and the measured Fibtem A5 with the aim of increasing the Fibtem A5 to 23 mm.
Discussion: The trial aims to provide evidence on the efficacy and safety of fibrinogen concentrate during acute
bleeding in an obstetric setting.
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Postpartum haemorrhage (PPH) is defined as blood loss
of ≥500 ml after vaginal delivery or ≥1000 ml after cae-
sarean section. Major PPH can be divided into moderate
at 1000–2000 ml or severe at over 2000 ml. Severe PPH
is also defined as a fall in haemoglobin of ≥40 g/l or the
need for transfusion of 4 or more units of red blood cells
(RBC) [1]. Massive PPH has been described as bleeds of
more than 2500 ml and is associated with significant
morbidity, even in resource-rich countries, including
admission to high dependency and intensive care and
emergency hysterectomy (6-8% of cases) [2].
PPH is a major cause of maternal morbidity and mor-
tality. Worldwide PPH accounts for at least 30% of all
maternal deaths [3], whilst in the UK massive PPH ac-
counts for 75% of severe childbirth-related morbidity af-
fecting 6:1000 deliveries each year [2]. The incidence of
massive PPH has increased over the last 10 years in the
UK and other countries [2,4-6] and outcomes have not
improved over that time period. Deaths directly caused
by obstetric bleeding in the UK have had an incidence
between 0.33 and 0.93 per 100,000 deliveries over the
last 15 years [7].
PPH results from a combination of physical causes
such as trauma, uterine atony and placental complica-
tions and is exacerbated by haemostatic impairment.
Haemostatic impairment is caused by a combination of
consumptive and dilutional coagulopathies. This leads to
low levels of fibrinogen early during PPH and before
clinically significant depletion of other coagulation fac-
tors [8]. The low fibrinogen level results in the forma-
tion of poor quality clots and contributes to on-going
bleeding. Bleeding is exacerbated by fibrinolysis (the
breakdown of fibrin clots), which is often increased dur-
ing PPH.
There are no high-quality data to guide the replace-
ment of coagulation factors during PPH. Coagulation
factors are often replaced with fresh frozen plasma
(FFP) but there is limited evidence to support its effi-
cacy. When as well as how much FFP to infuse in any
clinical situation is debated [9]. Current guidelines rec-
ommend identical haemostatic support during PPH as
for all other clinical situations of massive haemorrhage
[1,10,11]. There is limited evidence to support these
transfusion guidelines in any clinical situation and none
in PPH; studies in this area have been highlighted as a
priority [12].
Physiological changes in coagulation at the time of de-
livery mean that standard transfusion triggers, such as
those used in trauma (and recommended in current
guidelines), are unlikely to be applicable at the time of a
major PPH. At term the prothrombin time (PT) and ac-
tivated partial thromboplastin time (aPTT) are shorter
and fibrinogen is higher than in the non-pregnantpopulation. In addition, the PT and aPTT often remain
normal despite very large bleeds. The current recom-
mendation is to infuse FFP during PPH when the PT or
aPTT is greater than 1.5 times normal [1], but this is
not supported by any evidence and these coagulation ab-
normalities will be associated with established haemo-
static failure and microvascular bleeding [11]. Audit data
demonstrate that clinicians often do not follow these
recommendations in clinical practice when dealing with
severe PPH [8].
The fibrinogen level at the time of delivery is between
4–6 g/l compared to 1.5-4 g/l in the non-pregnant
healthy population. Current recommendations are to
maintain the fibrinogen level above 1 or 1.5 g/l [1,10,11].
During an on-going PPH it is not known whether fi-
brinogen should be replaced to a level appropriate to the
non-pregnant population or a level appropriate for the
time of delivery. There are data, however, suggesting that
a fibrinogen level associated with the time of delivery
might be more appropriate.
There are no systematic reviews of the use of fibrino-
gen concentrate in PPH; however, the fibrinogen level
has been shown to be a useful predictor of progression
from early to severe PPH in multiple studies. A fibrino-
gen level below 2.9 g/l, taken early during labour (before
any bleeding has occurred), had an odds ratio of 19 for
progression to PPH. In this study a fibrinogen of <2.9 g/l
had a positive predictive value (PPV) of 39% for progres-
sion to PPH whilst a fibrinogen above 2.9 g/l had a nega-
tive predictive value (NPV) of 94% [13]. In other studies,
a low fibrinogen level, taken early during a PPH, was
predictive of the need for invasive procedures or infu-
sion of RBC and FFP [14-16]. Charbit et al. found that a
fibrinogen level below 2 g/l, taken during an on-going
PPH, had a PPV of 100% for progression to severe
PPH, defined in part as the need for at least 4 units of
RBC, whilst a fibrinogen level above 4 g/l had a NPV of
85-90% [14]. Gayat et al. demonstrated that a fibrinogen
level below 2 g/l, taken after a 1000 ml estimated blood
loss, was an independent predictor for the need for an
invasive procedure [15].
Retrospective data from 240 women experiencing a
major PPH in a 6-month period, taken from the Cardiff
Maternity Database, also found that fibrinogen was a
useful predictor for progression to the need for RBC
transfusion. The receiver-operator characteristic curve
(ROC) area under the curve (AUC) (95% CI) for any
RBC transfusion was 0.78 (0.74-0.83), the need for 4
units of RBC 0.8 (0.73-0.86) and for progression to
2500 ml blood loss 0.85 (0.78-0.93). In women with a fi-
brinogen level less than 3 g/l, 18/21 (86%) required RBC
transfusion (median 3 units range 0–12) and 11 also
required FFP. The mean (SD) allogeneic units (RBC +
FFP + cryoprecipitate + platelets) infused was 5.8 (6.8). In
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4 g/l (a normal level for delivery) 7/81 (8.6%) required
RBC transfusion, a mean (SD) of 0.2 (0.6) units/woman,
and none required FFP. These data have been confirmed
in a prospective, consecutive cohort of 346 women in
Cardiff experiencing a major PPH that showed that the
ROC AUC (95% CI) for fibrinogen (n = 332) as a predict-
ive biomarker for the need for 4 or more units of RBC
transfusion was 0.77 (0.66-0.87).
Bleeding during PPH is often very fast and, in order to
reduce the risk of progression from moderate to massive
PPH, early intervention is required. If a low fibrinogen
level is to be used as a trigger for intervention the result
needs to be available to the clinician as soon as possible.
Testing fibrinogen in the laboratory takes between 60 to
90 min and this is too long to be clinically useful in most
cases of PPH. Furthermore, during a PPH the fibrinogen
level may fall rapidly and so repeated measurements
may be required to identify when a critically low level
has been reached. A better strategy would be to use
point-of-care testing to trigger a fibrinogen replacement
and to guide the dose to be given.
It is not possible to replace fibrinogen to levels nor-
mally associated with delivery with FFP because the con-
centration of fibrinogen in FFP is less than 4 g/l. In
addition, there is substantial delay between deciding to
give FPP and/or cryoprecipitate and its infusion. This is
because requesting FFP/cryoprecipitate from the labora-
tory, thawing it, issuing it and transporting it from the
laboratory to the delivery suite usually takes around
60 min even with an efficient system. Fibrinogen concen-
trate (RiaSTAP® manufactured by CSL Behring, Marburg,
Germany) can be used to rapidly replace fibrinogen to the
pregnancy-related normal range [17] and will be used in
this study. Anecdotal data suggest that fibrinogen concen-
trate may be useful as rescue therapy in managing severe
hypofibrinogenaemia associated with massive PPH. In a
number of case series, severe haemorrhage was clinic-
ally arrested or substantially improved when fibrinogen
concentrate was used during severe and on-going bleed-
ing [17-19].
A potential point-of-care surrogate test for the fibrino-
gen level is the Fibtem measured on the ROTEM® ma-
chine. The Fibtem assay gives results after 5 min (A5)
and at the time of maximum clot firmness (MCF). Pro-
spective data collected during major PPH in Cardiff have
shown that the A5 and MCF are strongly correlated
(r2 0.93) but the A5 is available a median (IQR) 19 (13–24)
min earlier than the MCF. The A5 is available on average
6 min after the start of the Fibtem assay. The A5 is be-
tween 1 and 2 mm lower than the MCF. The Fibtem A5
has been shown to correlate well with the laboratory-
measured fibrinogen level during early PPH [20] and a re-
sult is available within 10–15 min after taking blood. TheFibtem assay has been used successfully to guide fibrino-
gen replacement with fibrinogen concentrate following
complex cardiac surgery and was shown to have a large ef-
fect on bleeding and transfusion requirement [21].
In a Cardiff prospective observational study over a 12-
month period of 346 analysable women experiencing a
major PPH, 318 had a Fibtem performed and 332 had a
Clauss fibrinogen (in press) (NB: the paper includes one
more case than presented in this paper and hence the
results are not identical). In this cohort the utility of
Fibtem A5 and MCF to predict the need for red cell
transfusion was investigated. For the need for any red
cell transfusion, the ROC AUC (95% CI) for Fibtem A5
was 0.62 (0.55-0.69) and MCF was 0.62 (0.55-0.69), a re-
sult almost identical to that with the laboratory fibrino-
gen, 0.68 (0.61-0.75). Fibrinogen, Fibtem A5 and MCF
had improved utility for predicting larger bleeds: for the
need for 4 units of red blood cells the ROCs were 0.75
(0.64-0.87), 0.77 (0.67-0.87) and 0.78 (0.67-0.88) respect-
ively. The results for the need for eight or more units of
allogeneic products (red cells + FFP + platelets + cryopre-
cipitate) were 0.81 (0.70-0.92), 0.79 (0.67-0.91) and 0.79
(0.67-0.91) for fibrinogen, A5 and MCF respectively. This
supports the potential use of Fibtem A5 or MCF instead
of a laboratory fibrinogen level to guide treatment in this
situation. Given that A5 and MCF give equivalent infor-
mation and the A5 is available on average 19 min earlier
than MCF, it allows earlier intervention during major PPH
and hence is the preferred parameter to use for this study.
In the Cardiff prospective study there were 32 women
with a Fibtem A5 below 16 mm (or a Clauss fibrinogen
below 3 g/l) and on-going bleeding (>250 ml). Of these
27 (84%) required a red cell transfusion; mean (SD)
number of units of red cells transfused was 4.1 (3.9).
The mean (SD) number of units of allogeneic blood
products was 8.2 (8.7). Of the 32 women, 7 also received
between 3 and 7 g of fibrinogen concentrate as rescue
haemostatic therapy.
Of the 288 women who had a Fibtem A5 of 16 mm or
above or did not have on-going bleeding, and so would
not have been randomised in the prospective study, 64
(22%) received a red cell transfusion, mean (SD) 0.55
(1.20 units/woman). The mean (SD) number of allogen-
eic units was 0.79 (2.19). The PPV (95% CI) for the need
for a red cell transfusion of a Fibtem A5 below 16 mm
in women with on-going bleeding was 84 (67–94)%. The
NPV was 78 (73–82) %.
In the same study, of the 84 women with a Fibtem A5
of 23 mm or above, 16 (19%) received a red blood trans-
fusion [median (range) 2 (2–5) units]. The mean (SD)
number of units of red cells transfused was 0.44 (0.99)
with a median (IQR) of 0 (0–0) units. The mean (SD)
number of allogeneic units transfused was 0.58 (1.51)
with a median (IQR) of 0 (0–0) units.
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tem and fibrinogen levels, in women experiencing major
PPH, a Fibtem A5 of 16 mm is associated with a fibrino-
gen level below about 3 g/l and a Fibtem A5 of above
about 23 mm with a fibrinogen above 4 g/l (prospective
unpublished data from Cardiff and Huissoud 2009).
Objective
The aim of this study is to investigate whether infusion
of fibrinogen concentrate, based on the Fibtem A5 test,
during a moderately severe PPH reduces the total num-
ber of allogeneic blood products transfused after study
medication until discharged compared to placebo. The
effect of fibrinogen on efficacy endpoints will be assessed
as a secondary outcome.
Methods and design
Overview
This is a prospective, randomised, double-blind, placebo
controlled trial. A total of 60 women will be included
in the randomisation phase. The trial schema is shown
in Figure 1.Figure 1 Trial schema.Inclusion criteria
 Age 18 years or over,
 Gestation ≥24 + 0 weeks
 Women should have any one of the following either
before delivery or within 12 h after delivery:
haemorrhage of about 1500 ml and on-going bleed-
ing without another complication or haemorrhage of




o Cardiovascular instability (arterial blood pressure
below 90 mm/Hg and heart rate greater than 100 bpm)
o Clinical observation of microvascular oozing
Exclusion criteria
 Women who have documented that they do not want
to participate in the study during the antenatal period
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blood components
 Known inherited bleeding disorder
 Placenta accreta diagnosed antenatally
 Women who have already received uterine brace
sutures, uterine tamponade balloons, radiology
intervention or hysterectomy before entering the study
 Clinical suspicion of amniotic fluid embolism
 Secondary postpartum haemorrhage (defined as
abnormal bleeding starting between 24 h and
6 weeks after delivery).
Sample size
On the basis of data prospectively collected in Cardiff in
a study with the same entry criteria as this trial, the sam-
ple size was derived in the following way:
From a group of women with on-going bleeding (further
bleeding of ≥250 ml after enrolment) and with a Fibtem
A5 < 16 mm (representing women who would be the
control/placebo group), the total number of allogeneic
units (red cells + FFP + cryoprecipitate + platelets) trans-
fused was positively skewed. The data were therefore
transformed using the natural log (x + 1) transformation.
This resulted in a more normal distribution with a mean
[standard deviation (SD)] of 1.811 (1.004) on the log-
transformed scale. Back-transforming this data gives a
geometric mean of 5.12 units of allogeneic blood transfu-
sions. Using the data from low-risk women with Fibtem
A5 > 22 mm (representing what we would expect in the
intervention group) then using the same transformation,
the mean (SD) is 0.256 (0.539). Back-transforming gives a
geometric mean of 0.30 units of allogeneic blood transfu-
sions. This demonstrates a difference of 1.811-0.256 =
1.556 on the log-transformed scale.
A total of 60 patients can realistically be recruited. There-
fore basing our sample size calculation on 27 per group (54
in total plus a 10% dropout), if the mean on the transformed
scale in the intervention group is 1.036, this is the size of dif-
ference that we would be able to detect with power 80% at
the two-sided 5% alpha level [22]. A transformed mean of
1.036 corresponds to a back-transformed ‘geometric mean’
of 1.81 allogeneic units. This is a 3.3 unit reduction, when
measured as a simple difference on the original scale. The
size of difference between control and intervention groups
we might assume from this, when expressed on the log-
transformed scale, is 1.811-1.036 = 0.775.
In the light of the difference found between the high-
and low-risk groups (1.552), the assumption we are
making for the new study still appears to be cautiously
conservative. Thus we conclude that 27 individuals in
each treatment arm (54 in total) would give 80% power
to attain a difference of 3.3 total allogeneic units (0.775
on a log-transformed scale) at a conventional 5% alpha
level. Assuming a 10% loss to follow-up, this will enable60 women (30 per treatment group) to complete the
trial and achieve the above numbers.
Randomisation and blinding
Randomisation will be carried out using random per-
muted blocks. Computer-generated random numbers
will be produced to select a block of allocations from the
set of all possible permutations of allocations (on a 1:1
ratio) given a particular block size before the trial begins.
Saint Mary’s Pharmaceutical Unit will undertake an ex-
ercise to validate the blinding process. A reproducible
method that ensures all the fibrinogen does dissolve will
be developed and detailed guidance produced that will
form the basis of training the centre staff.
The fibrinogen concentrate will be supplied as vials of
1 g per bottle by CSL Behring to Saint Mary’s Pharma-
ceutical Unit (SMPU) in Cardiff. The placebo will be
50 ml of normal saline for each 1 g of fibrinogen. SMPU
will supply each site with packs of blinded fibrinogen
concentrate and placebo. At the time of randomisation
the next consecutive numbered study pack will be
opened. Black syringes will be used to draw the fibrino-
gen/placebo bottles with added diluents; the air will be
expelled from the syringe into a bag of Gelofusine.
SMPU has undertaken an exercise to validate the blind-
ing process and ensure that all the fibrinogen dissolves.
Observational phase
When women fulfil the study entry criteria they will
enter the observational phase (Figure 2). Standard ob-
stetric procedures for managing PPH (except those relat-
ing to blood product usage) such as suturing, removal of
retained products and surgical or tamponade treatments
for resistant atony will be followed according to local
and national guidelines and are at the discretion of the
treating clinicians. All other management will follow
standard local procedures and is at the discretion of the
treating clinicians. When women fulfil the criteria:
 Blood will be taken for full blood count (FBC),
coagulation screen and group and save/cross match
and sent to the routine laboratory for analysis.
These tests are part of standard care.
 At the same time as the routine blood tests, an extra
5-ml sample will be taken into a coagulation screen
bottle and a Fibtem test will be performed on a
ROTEM machine located in the delivery suite
or obstetric theatre.
 A measurement will be made of the blood loss
according to the procedures described below as
soon as possible after study entry.
If the Fibtem A5 is less than 16 mm, the bleeding is
on-going and the baby has been delivered, the woman
Figure 2 Observational phase.
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16 mm or above further Fibtem assays may be performed
after each 500 ml additional blood loss or for clinical con-
cern. If any subsequent Fibtem falls below 16 mm the
woman will enter the interventional phase (Figure 3).
Interventional phase
The participants are assigned either to placebo (isotonic
saline) or interventional drug (fibrinogen concentrate,
Riastap® CSL Behring, Marburg, Germany). The dose of
fibrinogen concentrate or placebo to be infused will be
calculated based on the woman's ideal body weight for
height and the measured FIBTEM A5 with the aim of
increasing the Fibtem A5 to 23 mm. The dose will be
calculated as: dose (g) = (23-actual Fibtem A5) × ideal
body weight for height/140. The dose will be rounded to
the nearest whole number of grams of fibrinogen andFigure 3 Interventional phase.the maximum dose of fibrinogen concentrate or placebo
will be 8 g. At the time of randomisation the following
will be done:
 Four units of FFP will be ordered from the blood
bank through routine procedures.
 A measurement of blood loss will be made at the
time the FFP is requested.
 Tranexamic acid (1 g) will be given intravenously, if
not already given. A further dose of 1 g can be given
intravenously if bleeding continues after 1 h of
the initial dose. Women should then receive
tranexamic acid 8 hourly, either orally or
intravenously, for a period of time determined
according to local practice.
 At about 15 min after the infusion of fibrinogen/
placebo a coagulation screen and sample for a
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results cannot be accessed by study staff until after
the decision has been taken to give or withhold the
FFP because they are likely to unblind the study. A
clinician can decide to access these results if the
clinical situation requires it but if this happens the
woman would not be included in the primary
efficacy analysis.
 Blood loss will be measured every 15 min, if feasible,
until the FFP arrives.
 An additional Fibtem and coagulation screen will be
taken at 24 h after the study medication, if possible
coinciding with a routine FBC.
The decision to give FFP will be taken by a team ap-
proach after consultation with either a consultant obstet-
rician and or a consultant obstetric anaesthetist. The
FFP will not be given if the bleeding has stopped and/or
the bleeding is slowing and the total blood loss is less
than 500 ml.
The FFP will be given if the bleeding is on-going and
there has been a further measured 500 ml blood loss
since the infusion of fibrinogen/placebo, if the bleeding
is on-going and the amount of bleeding has not reduced
between the first and last 15-min observation period fol-
lowing randomisation, and if the bleeding is on-going
and microvascular oozing or cardiovascular instability is
clinically apparent.
Subsequent haemostatic therapy
If bleeding continues after the initial 4 units of FFP, the
following protocol for blood product usage is suggested
but clinicians may deviate from this protocol on a case-
by-case basis for any reason:
Red blood cells will be transfused to maintain haemo-
globin level above 8 g/dl. Near-patient testing of haemo-
globin can be used.
The coagulation screen and FBC should be measured
through the routine laboratory and repeated after trans-
fusion of every 4 units of red blood cells or whenever
clinically indicated. Point-of-care coagulation testing
can be performed and the results acted on according to
local practice.
FFP can be transfused in a 1:1 red cell:FFP ratio until
bleeding has stopped, irrespective of coagulation results,
and even if results are unknown.
In addition, if the PT or aPTT is greater than 1.5 times
normal, a further 4 units of FFP can be given if bleeding
is on-going. After the first 4 units of FFP, and if the fi-
brinogen level is less than 1.5 g/l, the cryoprecipitate (10
units) or fibrinogen concentrate at a dose of 60 mg/kg
should be administered if bleeding is on-going. If the
platelet count is less than 75 × 109/l, 1 adult pool of
platelets should be given.Volume replacement
Crystalloid and colloid will be infused at the discretion
of the treating clinicians. The colloid will be a gelatine-
based product. The volume and time of infusions will be
recorded retrospectively from the patient’s notes. The
use of colloid hydroxyethyl starches will not be allowed
because these interfere with the FIBTEM assay.
Postnatal thromboprophylaxis
All women will receive postnatal thromboprophylaxis
with low molecular weight heparin. Low molecular weight
heparin will be commenced as soon as is practical after
bleeding has stopped.
Setting, location and follow-up
The study will recruit from four centres in the UK. The
criteria for selection are based on size of the centres (a
minimum of approximately 5500 deliveries per year) and
an interest in peripartum clinical studies. The study
team at each centre will be based on delivery suite and
consist of a lead obstetrician, obstetric anaesthetist and
midwife. All obstetricians, obstetric anaesthetists and
midwifes at each centre will be involved in the study.
Women recruited to the observational phase, but who do
not enter the interventional phase of the study, will be
followed up until hospital discharge. Women participating
in the interventional phase will be followed up until 6 weeks
following randomisation or death. At 6 weeks post-delivery,
women who entered the interventional phase of the study
will be contacted by telephone. The telephone interview
will obtain data on maternal hospital readmissions, inci-
dence of venous or arterial thrombotic events, and initi-
ation and duration of breastfeeding.
Outcomes and safety measures
The primary outcome is the total number of allogeneic
blood products transfused after the study medication
until discharge. The total number of allogeneic blood
products transfused will be compared between the two
arms. Secondary outcomes will be:
 the proportion of women receiving no allogeneic
blood products until discharge and within 24 h after
study medication,
 the number of units of red blood cells, FFP, platelets
and cryoprecipitate transfused after study
medication within 24 h and until discharge,
 the volume of cell salvaged blood transfused within
24 h after study medication and until discharge, the
total number of units of red blood cells, FFP,
platelets and cryoprecipitate transfused within 24 h
after the study medication, the total number of units
of red blood cells, FFP, platelets and cryoprecipitate
plus 1 unit for every 250 ml cell salvage transfused
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discharge, the measured abnormal blood loss within
24 h after study medication and until discharge, the
proportion of women requiring cryoprecipitate or
fibrinogen concentrate as subsequent therapy within
24 h after study medication and until discharge, the
change in Clauss fibrinogen and Fibtem parameters
before and 15 min and 24 h after the study
medication, the proportion of women requiring
invasive procedures (return to theatre, uterine brace
sutures, uterine tamponade balloons, radiology
intervention and hysterectomy) and the time of this
intervention within 24 h after study medication and
until discharge, incidence, duration and reasons for
not exclusive breastfeeding.
The effects of fibrinogen concentrate infusion on the
following safety endpoints will be explored: the propor-
tion of women requiring high dependency and intensive
care admission and length of stay, the total length of
hospital stay and the incidence of clinically diagnosed ar-
terial and venous thromboembolism within 6 weeks of
study medication.
Statistical methods and data analysis
Participant flow and recruitment
Summary statistics on eligibility, recruitment, withdrawal
and dropout will be collated for both arms and will form
the basis of the CONSORT flow diagram for clinical trial
reporting [23], specifically, for each arm, participants
randomly assigned, receiving intended intervention, com-
pleting the study protocol and analysed for the primary
outcome. Any protocol deviations will be described with
reasons as well as dates defining the period of recruitment
and follow-up.
Baseline data
Appropriate descriptive summaries and graphical illus-
trations of demographic and baseline clinical data (pre-
study medication) will be presented. Descriptive sum-
maries for selected variables will also be produced at site
level. Analyses by study arm will be performed when the
data collection for the final randomised patient has been
completed and all follow-up data obtained. Baseline data
will be used to check comparability between study arms
and generalisability of the study population. There will
be no formal testing of between-arm differences for any
variables at baseline.
Observational phase
Patients entering the observational phase but not rando-
mised to receive fibrinogen/placebo because of a Fibtem
A5 reading ≥16 will be described with regard to demo-
graphics and risk factors for PPH (such as pregnancy-relatedcomplications, labour and birth details, invasive procedures
required to control PPH, bleed volume, transfusion require-
ment) and compared to the patients in the interventional
phase. The whole cohort will be analysed to investigate risk
factors for severe PPH and the need for blood transfusion.
Interventional phase
The primary and secondary comparative analyses and
presentation of this randomised trial will be in accordance
with CONSORT guidelines and based on the intention-to-
treat (ITT) principle without imputation of missing values
(complete case population). The intention-to-treat popula-
tion uses all randomised participants in the groups they
were randomised to regardless of the intervention received
and the complete case population restricts the population
to include all randomised participants with complete data
and follow-up. ITT analysis with missing values imputed
will be undertaken as a sensitivity analysis.
Primary analysis
For those who enter the interventional phase of the
study, the primary outcome will compare the total num-
ber of units of allogeneic products (red blood cells, FFP,
cryoprecipitate, and platelets) transfused after study medi-
cation until discharge from hospital between women who
received fibrinogen concentrate and placebo. A Poisson
regression model will be used with due emphasis placed
on confidence intervals for the between-arm comparisons
with an investigation of site-level clustering. The primary
analyses will also be repeated controlling for any baseline
imbalances. While the main analyses will be based on ITT
without imputation, we will undertake sensitivity analyses
in order to estimate the effect of those randomised to
fibrinogen but not receiving it using complier average
causal effect (CACE) estimates, implemented in Stata using
instrumental variable regression [24].
Secondary analysis
Secondary analysis includes investigating the effect of fi-
brinogen on:
 the total number of units of allogeneic products
(red blood cells, FFP, cryoprecipitate and platelets)
transfused within 24 h after study medication;
 the individual number of units of red blood cells,
FFP, platelets and cryoprecipitate transfused after
study medication within 24 h and until discharge;
 the total number of units of allogeneic products red
blood cells, FFP, cryoprecipitate and platelets) plus 1
unit for every 250 ml cell salvage transfused within
24 h after study medication and until discharge,
and will be analysed using similar methods to those
used in the primary analysis.
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women receiving no allogeneic blood products, requiring
cryoprecipitate or fibrinogen concentrate as subsequent
therapy, and requiring invasive procedures, all within
24 h after the study medication and until discharge, will
be examined by fitting logistic regression models again
investigating for possible site-level clustering. The effect
of fibrinogen on the incidence of exclusive breastfeeding
will be explored using the same method.
Secondary outcomes also examined will be (1) the vol-
ume of cell-salvaged blood transfused within 24 h after
the study medication and until discharge (2) and the
measured abnormal blood loss within 24 h after study
medication until discharge. These outcomes will be ex-
amined using linear regression models. Each of the re-
gression model assumptions will be checked including
but not limited to examining the distribution of the re-
siduals and a plot of the residuals vs. predicted values.
Similarly, Clauss fibrinogen and Fibtem parameters at
15 min and 24 h after the study medication will be ex-
amined between arms using a linear regression model
adjusting for baseline measurements. The duration to
(1) stopping breastfeeding or expressing breast milk and
(2) any invasive procedure within 24 h after study medi-
cation and until discharge between arms will be exam-
ined using Cox’s proportional hazards model. Reasons
for not exclusive breastfeeding will also be explored by
using ordinal regression model.
The effects of fibrinogen concentrate infusion on the
following safety endpoints will be examined: the propor-
tion of women requiring high-dependency and intensive
care admission and length of stay, the total length of
hospital stay and the incidence of clinically diagnosed ar-
terial and venous thromboembolism within 6 weeks of
the study medication.
Consent
All women at each study centre will receive an information
leaflet in the antenatal period describing the study and
consent process. Women will have the opportunity to indi-
cate they would not wish to participate in the study at this
stage. Consent will be obtained prior to birth for women
planning an elective caesarean section or considered by a
clinician to be at high risk of PPH, and immediately prior
to study entry for other women. All women who give con-
sent during a PPH, or consent is given on their behalf by a
representative, will be seen by a member of the study team
within 24 h of enrolment, or as soon as the woman’s condi-
tion permits, to discuss their participation in the study and
obtain consent for use of the collected data.
Research governance/ethical considerations
Full ethical approval for this study has been obtained
from the Research Ethics Committee for Scotland (Ref:13/SS/0008). The study will be conducted in compliance
with the following:
 Declaration of Helsinki (Seoul, 2008)
 ICH Harmonised Tripartite Guideline for Good
Clinical Practice.
 The Medicines for Human Use (Clinical Trials)
Regulations 2004 (Statutory Instrument 2004 No.
1031) as amended by the Medicines for Human Use
(Clinical Trials) Amended Regulations 2006
(Statutory Instrument 2006 Nos. 1928 and 2984)
and Amended Regulations 2008 (Statutory
Instrument 2008 No. 941).
 Research Governance Framework for Health and
Social Care (Welsh Assembly Government 2nd
Edition, September 2009, and Department of Health
2nd Edition, July 2005).
Two external bodies, a Data Monitoring and a Trial
Steering committee will monitor the study progress.
Discussion
Postpartum haemorrhage is a major cause of maternal
morbidity and mortality. Fibrinogen appears to be a useful
biomarker to predict the progression from moderate to
massive PPH and the need for blood transfusion; however,
it is not known whether replacement of fibrinogen to levels
normal for the peripartum period (4–6 g/l), during an on-
going PPH, would reduce bleeding and the need for trans-
fusion. Although fibrinogen concentrate is not licensed for
use in obstetric haemorrhage in the UK, it has been used
off-label to correct hypofibrinogenaemia [17] and is the
recommended treatment in other countries [25].
This trial is designed to detect haemostatic impair-
ment rapidly and early during major PPH, identified by a
near patient Fibtem A5 test below 16 mm, and replace
fibrinogen to a level within the lower end of the normal
range associated with delivery. Laboratory tests of fi-
brinogen take about 60 min to become available, and
this is usually too slow to inform clinical intervention.
The Fibtem A5 result is available within about 10–15 min
of venesection and so can be used for decisions on thera-
peutic intervention. The decision to use the criteria of on-
going bleeding and a low for delivery Fibtem A5, rather
than a more pragmatic approach of randomising all
women with a specific estimate blood loss, was made to
minimise the chance of women being exposed to unneces-
sary IMP because many women in that situation would
have a fibrinogen level above 4 g/l and therefore be un-
likely to respond to a higher level The amount of fibrino-
gen concentrate or placebo given to all participants
allocated to the intervention group will be based on the
woman’s ideal weight for height and the Fibtem level. The
dose will be rounded to the nearest whole number of
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concentrate or placebo will be 8 g. The dose of fibrinogen
is designed to increase the Fibtem A5 and Clauss fibrino-
gen to the lower end of the normal range for delivery. This
level has been shown to be associated with a reduced re-
quirement for blood products. This approach was pre-
ferred to the pragmatic approach of giving a standard
dose of fibrinogen because this would be likely to be asso-
ciated with both under- and over-dosing. The lower end
of the normal range has been targeted to minimise the risk
of thrombosis.
The study is designed to be blinded until the decision to
give the first 4 units of FFP has been taken and hence the
Fibtem A5 taken 15 min after IMP is not known to the
clinicians managing the case. The primary endpoint is a
comparison of allogeneic products between the two arms
and knowledge of whether fibrinogen or placebo had been
given is likely to affect the decision to give FFP, cryopre-
cipitate and fibrinogen. After the first FFP has been given
and if the bleeding is on-going, clinicians need to know
the fibrinogen level to optimally manage the case. At this
point Fibtem A5 and Clauss fibrinogen tests can be per-
formed that are available to clinicians. This will have the
effect of partially unblinding the study because clinicians
will know whether the Fibtem has increased or not. This
partial unblinding was deliberately included in the study
for women with on-going bleeding for safety reasons.
The primary objective is to investigate whether infu-
sion of fibrinogen, based on a Fibtem A5 test, during a
moderately severe PPH reduces the total number of allo-
geneic blood products (FFP, red blood cells, platelet con-
centrates and cryoprecipitate) transfused after study
medication until discharge compared to placebo. This
was chosen because the alternative primary endpoint of
estimated blood is very difficult to measure accurately
and reproducibly, especially in a multicentre study.
At the time of a PPH women may not have full cap-
acity to give informed consent because of factors such
as pain, altered levels of consciousness due to drugs and
blood loss and anxiety. In addition, some clinical situa-
tions are so acute that there will be insufficient time to
read and understand a full patient information sheet.
The consent procedures adopted in this trial are based
on recommendations of the Royal College of Obstetri-
cians and Gynaecologists for obtaining consent to re-
search in labour, which recommend against taking
antenatal consent from all women if the likelihood of
the event is less than one in ten deliveries [26].
Trial status
The trial was initiated in June 2013. By November 2013,
all four centres were screening and recruiting partici-
pants. By March 2014, 16 participants had been included
in the randomisation phase.Abbreviations
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